Close menu
- Home
- About CW
-
Topics
- Back to parent navigation item
- Topics
- Accounting & Auditing
- AI
- AML
- Anti-Bribery
- Boards & Shareholders
- Culture
- ESG/Social Responsibility
- Ethics & Culture
- Europe
- Financial Services
- Internal Controls
- Regulatory Enforcement
- Regulatory Policy
- Risk Management
- Sanctions
- Surveys & Benchmarking
- Supply Chain
- Third Party Risk
- Whistleblowers
- Opinion
- Events
- Webcasts
- Research
- Membership
Novartis Faces China Bribery Probe
By Jaclyn Jaeger2013-09-18T09:57:00
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Blog
Novartis to pay $25 million in FCPA case
2016-03-24T13:15:00Z By Jaclyn Jaeger
Switzerland pharmaceutical giant Novartis yesterday reached a $25 million settlement with the Securities and Exchange Commission for violating the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act concerning its operations in China.
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Info
- © 2025 Compliance Week
Site powered by Webvision Cloud